ARTICLE | Clinical News
AOM updates Phase II ovarian cancer data
October 25, 2001 7:00 AM UTC
AnorMed (TSE:AOM) said updated Phase II ovarian cancer data on ZD0473, a platinum-based therapeutic designed to overcome platinum drug resistance in cancer patients, showed a response in 12 of 31 (39%...